19 completed. 19 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Completed 19 |
Follow Neisseria Meningitidis: new trials by email Literature Review of Neisseria Meningitidis trials Research Report on Neisseria Meningitidis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age Hib-MenCY-TT (MenHibrix®), Pediarix®, Rotarix® - Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 600 | 2014-02-01 | 2018-09-14 |
| Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010) PR5I, Pediacel®, NeisVac-C® - Neisseria Meningitidis, Bacterial Infections | Phase 3 | Completed | MCM Vaccines B.V. | 385 | 2013-05-01 | 2019-02-25 |
| Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination Hexavalent vaccine, NeisVac-C, Prevenar 13 - Neisseria Meningitidis, Bacterial Infections | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 350 | 2013-04-01 | 2017-09-11 |
| Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC) MenBvac - Neisseria Meningitidis | Phase 3 | Completed | University Hospital, Rouen | 120 | 2012-04-01 | 2026-06-12 |
| Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) V419, PREVNAR 13®, MCC-TT - Neisseria Meningitidis, Bacterial Infections | Phase 3 | Completed | MCM Vaccines B.V. | 284 | 2012-03-30 | 2019-03-28 |
| NeisVac-C Single Prime Study in Infants Meningococcal group C polysaccharide conjugate vaccine, Pneumococcal 13-valent conjugate vaccine, Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine - Neisseria Meningitidis | Phase 3 | Completed | Pfizer | 956 | 2010-09-01 | 2015-05-21 |
| Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines MenitorixTM, Pneumococcal conjugate vaccine GSK1024850A, PrevenarTM - Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 582 | 2009-05-14 | 2018-02-15 |
| Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants Menitorix™, Infanrix™ penta, Prevenar™ - Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 3 | Completed | GlaxoSmithKline | 313 | 2007-12-01 | 2018-08-27 |
| Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age. GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014), PedvaxHIB, Prevnar - Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 3 | Completed | GlaxoSmithKline | 4021 | 2007-07-01 | 2016-11-29 |
| Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine, Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine - Neisseria Meningitidis, Meningococcal Infections | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 450 | 2007-02-01 | 2015-07-14 |
| Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB MenHibrix (Hib-MenCY-TT), Hib conjugate vaccine (ActHIB) - Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 270 | 2006-09-01 | 2016-12-16 |
| Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta - Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 3 | Completed | GlaxoSmithKline | 4432 | 2006-09-01 | 2016-12-16 |
| Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years. Haemophilus influenzae type b and meningococcal serogroup C (vaccine), Priorix™, Hiberix™ - Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 3 | Completed | GlaxoSmithKline | 433 | 2006-06-01 | 2018-08-24 |
| Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC Haemophilus influenzae type b- and meningococcal (vaccine), Infanrix™ penta, Infanrix™ hexa - Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 3 | Completed | GlaxoSmithKline | 230 | 2006-05-01 | 2016-10-20 |
| Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine Haemophilus influenzae type b- and meningococcal serogroup C (vaccine), Infanrix Penta, Infanrix hexa - Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 709 | 2006-04-01 | 2016-10-07 |
| Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine, ActHIB, PedvaxHIB - Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 3 | Completed | GlaxoSmithKline | 4441 | 2006-02-22 | 2018-08-24 |
| Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197 Haemophilus influenzae type b- and meningococcal (vaccine) - Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 3 | Completed | GlaxoSmithKline | 297 | 2005-03-01 | 2016-09-21 |
| Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine Haemophilus influenzae type b- and meningococcal (vaccine) - Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 3 | Completed | GlaxoSmithKline | 478 | 2005-02-01 | 2016-09-21 |
| Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects Haemophilus influenzae type b- and meningococcal (vaccine) - Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 468 | 2004-11-01 | 2016-09-16 |
Haemophilus Infections (13) · Bacterial Infections (3) · Virus Diseases (3) · Meningococcal Infections (2)
Bacterial Infections and Mycoses (17) · Infections (17) · Bacterial Infections (14) · Gram-Negative Bacterial Infections (14) · Pasteurellaceae Infections (13) · Neisseriaceae Infections (2)
Vaccines (7) · 13-valent pneumococcal vaccine (5) · Measles-Mumps-Rubella Vaccine (5) · Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (3) · Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (3) · Heptavalent Pneumococcal Conjugate Vaccine (3) · PEDIARIX (3) · Chickenpox Vaccine (2) · Hepatitis B Vaccines (2) · Hib-MenCY-TT vaccine (2) · RotaTeq (2) · Vaxelis (2) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (2) · Engerix-B (1) · Hepatitis A Vaccines (1)
GlaxoSmithKline (13) · MCM Vaccines B.V. (2) · Sanofi Pasteur, a Sanofi Company (2) · Pfizer (1) · University Hospital, Rouen (1)
Spain (6) · United States (5) · Mexico (3) · Poland (3) · Australia (2) · Finland (2) · France (1) · Germany (1) · Italy (1) · Saudi Arabia (1) · United Kingdom (1)
PMID 22327493, PMID 18463125, PMID 23340564, PMID 27145999, PMID 27939054, PMID 28583305, PMID 30471953